Medable partners with Masimo to bring wearable devices to clinical trials and capture better data –

What you should know:

– Medable Inc., a leader in advanced clinical research technologies, announced a groundbreaking partnership with Masimo (NASDAQ: MASI) to integrate medical-grade mobile devices into clinical trials. The goal of this collaboration is to improve patient participation and data collection for clinical trials.

“By offering a patient-centric approach and supporting richer data collection, this collaboration holds the promise of faster drug development, improved patient experiences, and ultimately, advancements in healthcare.”

Relieving patients

Masimo’s MightySat® Rx Pulse Oximeter, a trusted medical device used by physicians around the world, is now being incorporated into the Medable platform. This eliminates the need for frequent, often burdensome trips to research centers for routine tests, which is especially beneficial for patients with serious diseases such as lung and breast cancer. This technology is already used by over 3,000 patients participating in eight large oncology trials in 25 countries.

A multifaceted approach to data collection

Collaboration goes beyond wearables. Medable’s eCOA+ solution enables the collection of subjective data through human interaction. Combined with objective data from Masimo sensors, this creates a richer and more comprehensive dataset for researchers. Medable selected Masimo for its signal extraction technology, known for delivering accurate readings even in challenging conditions.

Wearable devices are gaining popularity in clinical trials

The use of wearable devices in clinical trials is increasing. Currently, 20% of studies using the Medable platform involve wearable devices, and 35% of them focus on oncology research. This trend highlights the growing recognition of the potential of wearables to improve patient experiences and data collection.

Financial benefits of decentralized research

Research from the Tufts Center for the Study of Drug Development further supports the case for decentralized research. Their findings suggest that decentralized research can deliver a net financial benefit of 5 to 13 times that of Phase II and III trials, translating into a potential return on investment of $10 million and $39 million, respectively, with an average investment of $500,000 and $1.5 million in Phases II and III. 3rd trial respectively.

“Medable has always been a leader in digital and decentralized clinical trials, and we are excited to partner with a forward-thinking organization that has the ambition and ability to transform research,” said Dr. Daniel Cantillon, chief medical officer at Masimo. “Clinical research requires best-in-class accuracy and data quality, both on-site and outside clinical offices. Medable solves this problem through its support and enabling more patients to participate in trials. Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”